Cargando…
Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone
CONTEXT: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an improved metabolic profile compared to conventional 3-times-daily (TID-HC) therapy among patients with primary adrenal insufficiency. This effect might be related to a more physiological cortisol pro...
Autores principales: | Espiard, Stéphanie, McQueen, Johanna, Sherlock, Mark, Ragnarsson, Oskar, Bergthorsdottir, Ragnhildur, Burman, Pia, Dahlqvist, Per, Ekman, Bertil, Engström, Britt Edén, Skrtic, Stanko, Wahlberg, Jeanette, Stewart, Paul M, Johannsson, Gudmundur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947853/ https://www.ncbi.nlm.nih.gov/pubmed/33236103 http://dx.doi.org/10.1210/clinem/dgaa862 |
Ejemplares similares
-
Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017) -
SAT302 Circulating And Urinary Metabolites Associated With Total Exposure Of Cortisol And Cortisol Time Profile
por: McQueen, Johanna, et al.
Publicado: (2023) -
Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
por: Nilsson, A G, et al.
Publicado: (2014) -
OR30-06 Hospitalisation, Intensive Care And Death Due To COVID-19 In Swedish Patients With Adrenal Insufficiency
por: Bergthorsdottir, Ragnhildur, et al.
Publicado: (2023) -
Psychotropic Drugs in Patients with Cushing’s Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study
por: Bengtsson, Daniel, et al.
Publicado: (2021)